Suggested remit: To appraise the clinical and cost effectiveness of dostarlimab with carboplatin and paclitaxel within its marketing authorisation for treating recurrent or advanced endometrial cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 3968

Provisional Schedule

Final draft guidance 05 March 2024 - 19 March 2024
Expected publication 03 April 2024

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Stakeholders

Companies sponsors GlaxoSmithKline
Others Department of Health and Social Care
  NHS England
Patient carer groups Peaches Womb Cancer Trust
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies MSD
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
05 December 2023 Committee meeting: 1
16 May 2023 Invitation to participate
27 March 2023 Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Dostarlimab with carboplatin and paclitaxel for treating recurrent or advanced endometrial cancer have been revised. It is anticipated that the appraisal will begin in mid-May 2023 when we will write to you about how you can get involved.
30 January 2023 - 20 February 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3968
27 October 2022 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Dostarlimab with carboplatin and paclitaxel for treating recurrent or advanced endometrial cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid-April 2023
24 November 2021 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual